<DOC>
	<DOCNO>NCT00116116</DOCNO>
	<brief_summary>The purpose study evaluate whether therapy daily regimen stavudine extend release ( d4T XR ) , lamivudine ( 3TC ) , efavirenz ( EFV ) lead improved outcome , measure viral load , CD4 count , adherence , safety , tolerability .</brief_summary>
	<brief_title>DART II - A Phase IV Study 3 Antiretroviral Medicines Combination , HIV Patients Who Have Not Been Previously Treated With Antiretroviral Therapy</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Patients 18 year age older infect HIV weigh least 40 kg . Plasma HIV RNA viral load 1000 copies/mL great CD4 count 100 cells/mL great . Be willing use two form contraception throughout study . No previous exposure antiretroviral ( ARV ) drug Pregnancy breastfeed Physical psychiatric disability Proven suspect acute hepatitis within 30 day prior study entry Active AIDSdefining opportunistic infection disease History acute chronic pancreatitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>HIV/AIDS</keyword>
</DOC>